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Summary
Environmental cues associated with nicotine delivery
are an important part of the stimulus that sustains
smoking behavior and is often coupled with craving
and relapse; however, the neuronal circuitry and mo-
lecular substrates underlying this process are still
poorly understood. Exposure to an environment pre-
viously associated with rewarding properties of nico-
tine results in an increase of CREB phosphorylation
similar to that seen following nicotine administration,
and this response is absent in MOR−/− mice. More-
over, a single administration of an opioid receptor
antagonist, naloxone, blocks both the conditioned
molecular response (CREB phosphorylation) and the
conditioned behavioral response (nicotine reward) in
a place preference paradigm. Lastly, repeated nico-
tine administration results in increased expression of
MORs. However, this effect, along with rewarding
properties of nicotine, is blocked in mice with a tar-
geted disruption in the CREB gene. Together, pharma-
cologic and genetic manipulations indicate that phos-
phorylation of CREB and upregulation of functional
MORs are required for nicotine-conditioned reward.
Introduction
Nicotine is believed to be the primary factor responsi-
ble for the addictive properties of cigarettes; however,
the mechanism underlying its reinforcing effects re-
mains elusive. Tobacco use is the leading preventable
cause of death in the United States, with one in every
five deaths attributed to smoking (Peto et al., 1992).
Current therapeutic interventions for smoking cessa-
tion are inadequate (Vaszar et al., 2002); thus, insights
into the molecular and genetic mechanisms that un-
derlie the addictive properties of nicotine would prove
useful in creating successful treatment programs for
smoking cessation.
Nicotine stimulates cholinergic receptors located in
the ventral tegmental area (VTA) and nucleus accum-
bens (NAc), which are important neural substrates in
the mesolimbic dopamine reward pathway (Dani and
Heinemann, 1996). Several studies indicate that an in-
crease in dopamine in the NAc is an integral compo-
nent underlying the reinforcing properties of many
drugs of abuse (Berridge and Robinson, 1998; Di Chiara
and Imperato, 1979), including nicotine (Corrigall and
Coen, 1991; Corrigall et al., 1994; Di Chiara, 2000).
Specifically, studies in mice lacking the β2 subunit of*Correspondence: blendy@pharm.med.upenn.eduthe neuronal nicotinic acetylcholine receptor show de-
creased nicotine-induced dopamine release in the ven-
tral striatum and decreased nicotine self-administration
(Picciotto et al., 1998).
While the role of dopamine in mediating reinforcing
properties of nicotine is fairly well established, less is
known about the influence of other neurotransmitter
systems. Recently, the role of endogenous opioids has
been investigated in nicotine action. Nicotine has been
shown to cause a release of endogenous opioids in the
NAc of rat and striatum of mouse (Davenport et al.,
1990; Dhatt et al., 1995; Houdi et al., 1991; Pierzchala
et al., 1987; Pomerleau and Pomerleau, 1984), and in-
terference with the endogenous opioid system has
consequences for a number of nicotine-mediated re-
sponses. For example, the opioid receptor antagonist
naloxone has been shown to block or attenuate nico-
tine-induced increases in food responding (Corrigall et
al., 1988), nicotine-induced analgesia (Aceto et al.,
1993), as well as withdrawal or aversion in nicotine-
dependent animals (Ise et al., 2000; Malin et al., 1993).
Likewise, studies in the -opioid receptor knockout
mouse (MOR−/−) demonstrate that this receptor is re-
quired for nicotine-induced antinociception and re-
warding effects of nicotine (Berrendero et al., 2002). In
humans, smoking appears to be closely linked to opioid
drug use (Mello et al., 1980), and endogenous opioid
levels are increased following smoking (Pomerleau et
al., 1983). Finally, humans that carry a -opioid receptor
(MOR) variant (Asn40Asp) are more likely to remain ab-
stinent at the end of nicotine cessation treatment (Ler-
man et al., 2004). Taken together, these studies suggest
that MORs have a critical role in mediating nicotine re-
ward; therefore, smoking cessation therapies that tar-
get the MOR should be highly effective.
The transcription factor CREB is thought to play a
major role in the rewarding properties of many drugs of
abuse. Several studies have correlated changes in
CREB protein and activation with morphine administra-
tion (Guitart et al., 1992; Lane-Ladd et al., 1997; Windell
et al., 1996), and mice that harbor a mutation in the
CREB gene (CREBα mutant mice) (Blendy et al., 1996)
do not find morphine reinforcing (Walters and Blendy,
2001). Chronic cocaine increases CREB phosphoryla-
tion in the NAc (Kano et al., 1995a; Terwilliger et al.,
1991); however, viral-mediated overexpression of CREB
in this region decreases the reinforcing properties of
cocaine (Carlezon et al., 1998). Moreover, overexpres-
sion of a mutant form of CREB increased the reinforcing
properties of cocaine (Carlezon et al., 1998). Similar ef-
fects are seen in CREBaD mutant mice, which are more
responsive to the reinforcing effects of cocaine com-
pared to wild-type littermates (Walters and Blendy,
2001).
Few studies have examined the relationship between
reinforcing properties of nicotine and CREB. Chronic
nicotine administration in mice results in decreased
CREB phosphorylation in the NAc but increased CREB
phosphorylation in the prefrontal cortex, while nicotine
withdrawal increases CREB phosphorylation in the VTA
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lchronic nicotine in rats decreases CREB, phosphory-
lated CREB, and CRE-DNA binding in the cortex and b
camygdala (Pandey et al., 2001). Thus, the role of CREB
in mediating the long-term plasticity that may underlie w
pthe development of nicotine addiction is poorly under-
stood. u
jHuman imaging, clinical, and laboratory studies indi-
cate that nicotine craving and smoking relapse can be r
itriggered by environmental cues associated with smok-
ing behavior (Brody et al., 2002; Childress et al., 1999). t
tAs smokers self-administer nicotine within the context
of specific environmental stimuli, cues may not only in- l
fluence the degree to which nicotine is self adminis-
tered, but they may become as important to smoking c
rbehavior as nicotine itself (Caggiula et al., 2002). There-
fore, the goals of the present studies were to determine r
dwhat molecular mechanisms are activated during nico-
tine administration, if these mechanisms are similarly c
oengaged during reexposure to environmental cues as-
sociated with nicotine delivery, and whether these mech- 0
panisms are necessary and sufficient to sustain the be-
havioral responses associated with nicotine reward. p
L
eResults
l
pTo investigate the mechanisms underlying nicotine
nreinforcement, we examined the activation of CREB
wvia phosphorylation (pCREB). Twenty minutes follow-
ting acute nicotine treatment, pCREB-positive cells are
tmarkedly increased in the VTA (Figure 1). To evaluate
cthe effect of opioid receptor blockade on this response,
swe examined the levels of pCREB following acute nico-
ltine in animals that had been pretreated with naloxone.
gNicotine-induced increases in pCREB are blocked in
nthe VTA with naloxone pretreatment (Figure 1).
Naloxone has some affinity for all subtypes of opioid
ireceptors. Therefore, to establish the specificity of this
oantagonist, we utilized MOR−/− mice and examined
ipCREB induction in the VTA after an acute injection of
jnicotine. In the wild-type animals, nicotine treatment
nresulted in an increase in pCREB-positive cells in the
pVTA (Figure 2) as seen previously; however, nicotine-
Tinduced increases in pCREB were absent in the MOR−/−
pmice (Figure 2). These data confirm that the ability of
onaloxone to attenuate nicotine-induced increases in
tpCREB occurs through the MOR.
pTo examine the extent to which nicotine increases
tCREB phosphorylation throughout the brain, we mea-
(sured pCREB levels in a number of brain regions asso-
aciated with reward, dopamine signaling, and learning
tand conditioning. In addition to the VTA, pCREB levels
owere increased in the NAc, striatum, and pedunculo-
epontine tegmental nucleus (PPT) following a single ad-
cministration of nicotine (Figure 3). In contrast, pCREB
Plevels were not affected in the substantia nigra, hippo-
tcampus, or cingulate cortex by acute nicotine admin-
tistration (Figure 3).
vThe rewarding or aversive effects of drugs can be
devaluated through the use of conditioned place prefer-
tence. During the course of the experiment, mice are
nconfined to one side of a testing chamber or the other
and receive nicotine (for details, see Experimental Pro- tedures). On test day, animals are drug free and al-
owed to roam between the two sides. If a drug has
een experienced as reinforcing, animals will spend
onsiderably more time on the side of the chamber that
as paired with the drug. To examine the effects of re-
eated nicotine administration on pCREB levels, we
tilized the same number and frequency of nicotine in-
ections used in the behavioral assessment of nicotine
eward. Of interest, pCREB levels were increased only
n the VTA and striatum 20 min following repeated nico-
ine (Figure 3). However, 24 hr following repeated nico-
ine administration there were no increases in pCREB
evels in any brain regions examined (Figure 3).
Although acute and repeated nicotine administration
learly increases CREB phosphorylation in some brain
egions, it is not known whether exposure to an envi-
onment previously paired with nicotine is able to in-
uce a similar effect. Therefore, we trained mice in a
onditioned place preference paradigm with 1.0 mg/kg
r 2.0 mg/kg nicotine. Lower doses of nicotine (0.1,
.25, and 0.5 mg/kg) did not produce any significant
reference or aversion (data not shown), and levels of
CREB were not evaluated following these doses.
evels of pCREB were examined immediately following
xposure to the place preference chambers, 24 hr fol-
owing the last nicotine administration. While levels of
CREB were not increased in animals that received
icotine in their home cage at this time, pCREB levels
ere significantly increased in the VTA, cingulate cor-
ex, NAc, and PPT in animals that had prior exposure
o nicotine in the conditioning boxes (Figure 3). The in-
rease in the NAc and PPT may be due in part to the
ignificant increase in pCREB levels in response to sa-
ine conditioning alone, while increases in VTA and cin-
ulate cortex appear to be specific to exposure to the
icotine-conditioned environment (Figure 3).
As acute nicotine administration induced increases
n pCREB that were blocked by pretreatment with nal-
xone, the effects of naloxone on environment-induced
ncrease in pCREB were examined as well. A single in-
ection of naloxone administered 24 hr after the last
icotine injection blocked the conditioned increase in
CREB in both the VTA and NAc (Figures 4A and 4B).
he behavioral significance of blocking CREB phos-
horylation after exposure to an environment previ-
usly paired with nicotine was determined in condi-
ioned place preference experiments. Animals in which
CREB was elevated showed significant preference to
he nicotine-paired side of the conditioning chamber
Figure 4C). In contrast, at a higher dose (2.0 mg/kg),
nimals found nicotine aversive as indicated by the fact
hat animals spend significantly less time on the side
f the chamber that was paired with nicotine. Of inter-
st, a dose of 2.0 mg/kg of nicotine did not produce a
hange in pCREB levels in the VTA (data not shown).
retreatment with naloxone on test day only blocked
he reinforcing effects of nicotine at 1.0 mg/kg but not
he aversive effects seen at 2.0 mg/kg. These data re-
eal that activation of CREB is associated with the con-
itioned behavioral reward expressed following nico-
ine place preference. Moreover, a single injection of
aloxone on the test day was sufficient to attenuate
his increase in environment-conditioned CREB phos-
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935Figure 1. The Opioid Antagonist Naloxone
Blocks the Nicotine-Induced Increase in
phospho-CREB-Positive Cells in the VTA af-
ter an Acute Injection
Animals were pretreated with an injection of
either saline or naloxone (1 mg/kg s.c.) fol-
lowed 5 min later by an injection of saline or
nicotine (1 mg/kg i.p.) and then sacrificed af-
ter 15 min. (A) Saline pretreatment with sa-
line treatment (black bar indicates 100 m).
(B) Naloxone pretreatment with saline treat-
ment. (C) Saline pretreatment with nicotine
treatment. (D) Naloxone pretreatment with
nicotine treatment. (E) Stereotaxic atlas rep-
resentation of the section corresponding
to bregma −3.88 mm. Shaded square indi-
cates the region of the high-power micro-
graphs that surround the border of the VTA
where the phospho-CREB-positive cells were
counted. (F) Quantification of phospho-CREB-
positive cells in the VTA. Open bars are sa-
line-pretreated animals, and closed bars are
naloxone-pretreated animals. *p < 0.05 from
corresponding saline pretreatment group
and corresponding nicotine-treated group
[F(3, 20) = 97.646; ANOVA with a Bonferroni-
Dunn post hoc; n = 6 per group; mean
counts ± SEM].quent alterations in the expression of conditioned place
Figure 2. pCREB in the VTA Is Increased after an Acute Nicotine
Injection in Wild-Type but Not -Opioid Knockout Mice
Mice were treated with nicotine (1 mg/kg) and perfused 20 min
later, and brains were processed for pCREB immunohistochem-
istry. The x axis represents treatment, and the y axis represents the
number of pCREB-positive cells counted in the VTA. The open bars
are wild-type, and the closed bars are -opioid receptor knockout
mice. *p < 0.05 from wild-type saline group and mutant nicotine
group [F(3, 12) = 11.427; ANOVA with a Bonferroni-Dunn post hoc;
n = 4 per group; mean counts ± SEM].phorylation and to block the rewarding effects of nic-
otine.
To examine the specificity of the effects of MOR
blockade, including changes in pCREB and subse-preference, naloxone was administered on test day of
a cocaine-conditioned place preference paradigm. Be-
havioral responses and changes in pCREB levels in the
VTA and NAc were examined. In the VTA, there was
no effect of cocaine-conditioned place preference on
pCREB levels, nor was there an effect of naloxone pre-
treatment (Figure 5A). In contrast, there was an in-
crease in pCREB levels in the NAc on test day, but
unlike nicotine conditioning, this increase was not af-
fected by pretreatment with naloxone (Figure 5B). Nal-
oxone administration on test day did not block the
expression of cocaine-conditioned place preference
(Figure 5C). These data suggest that the effects of nal-
oxone on pCREB levels as well as conditioned behavior
are specific to nicotine and not generalized to cocaine.
Pharmacologic tools, such as naloxone, allow us
to manipulate the activity of CREB indirectly through
modulation of the opioid receptor. To directly examine
CREB activity, and the functional significance of these
increases in pCREB, we utilized CREBaD mutant mice
in conditioned place preference for nicotine. We pre-
viously found that the rewarding properties of morphine
are completely absent in these mice (Walters and
Blendy, 2001). This is not due to a general deficit in
reward-mediated behavior in these animals, as both
cocaine and food CPP are present in CREBaD mutant
mice (Walters and Blendy, 2001; and unpublished data).
Here, we demonstrate that the rewarding properties of
nicotine at 1.0 mg/kg were absent in the CREBaD mu-
Neuron
936Figure 3. Phospho-CREB-Positive Cell Counts
in Several Brain Areas after Nicotine Treatment
The y axis represents the number of pCREB-
positive cells. The x axis represents various
drug treatment paradigms. Home cage 1X
represents single injection (i.p.) of saline or
nicotine in the home cage, with the animal
killed 20 min after injection. Home cage 4X
(20 min) represents repeated injection (i.p.)
of saline or nicotine, every other day in the
home cage, for 8 days, with the animal killed
20 min after last injection. Home cage 4X (24
hr) represents repeated injection (i.p.) of sa-
line or nicotine, every other day in the home
cage, for 8 days, with the animal killed 24 hr
after last injection. CPP box 4X (24 hr) repre-
sents repeated injection (i.p.) of saline or nic-
otine, every other day, in conditioning place
preference boxes, for 8 days, with the animal
killed 24 hr after last injection, immediately
following exposure to conditioning boxes.
*p < 0.05 from corresponding saline group,
+p < 0.05 from corresponding home cage
group. All statistics were done by ANOVA
with a Fisher’s post hoc; n = 6–8 per group;
mean counts ± SEM. [VTA, F(7, 41) = 85.996;
NAc, F(7, 41) = 9.480; cingulate cortex, F(7,
33) = 1.133; substantia nigra, F(7, 33) =
0.724; striatum, F(7, 33) = 5.738; PPT: F(7,
33) = 9.285; hippocampus, F(7,41) = 4.907].tant mice (Figure 6). In contrast, the aversive properties s
tof nicotine, evident at 2.0 mg/kg, were not altered by
CREB deficiency and were comparable to the response T
fseen in wild-type controls.
The present data demonstrate that a genetic defi- d
cciency (CREB mutation) and a pharmacological manip-
ulation (MOR antagonism) have remarkably similar ef- l
mfects on rewarding properties of nicotine. However, one
caveat of genetic models such as CREBaD mutant mice t
tis that functional compensation can occur due to the
absence of the gene product throughout development. e
mThus, putative CREB target genes, such as the MOR,
which contains a CRE sequence in its promoter (Min et
Mal., 1994), could be particularly susceptible to altered
regulation in these mice. However, there was no differ- M
ience in MOR mRNA levels in the VTA and NAc between
wild-type and CREBaD mutant mice (Figure 7A), sug- f
lgesting that constitutive loss of CREB had not altered
any systems responsible for the basal regulation of the o
PMOR gene in these areas. In contrast, repeated nicotine
administration in the conditioned place preference par- s
Cadigm (1.0 mg/kg, once every other day for 8 days) re-ulted in an increase in MOR mRNA in the VTA in wild-
ype mice but not in CREBaD mutant mice (Figure 7A).
his upregulation of MOR mRNA appears to be specific
or nicotine, as MOR mRNA levels were not significantly
ifferent in wild-type or CREBaD mutant mice following
ocaine administration. Furthermore, within the meso-
imbic dopamine reward pathway, this increase in MOR
RNA was specific to the VTA, as levels were not al-
ered in the NAc (Figure 7B). While cocaine administra-
ion induced changes in MOR mRNA in the NAc, this
ffect is equivalent in wild-type and CREBaD mutant
ice.
To determine if the nicotine-dependent changes in
OR mRNA levels are due to a direct activation of the
OR gene by CREB, we performed in vivo chromatin
mmunoprecipitation (ChIP) assays. ChIPs were per-
ormed using chromatin obtained from the VTA of sa-
ine- and nicotine-treated mice. To quantify the degree
f MOR promoter enrichment, we performed real-time
CR of the immunoprecipitated material with primers
urrounding the CRE. Chromatin precipitation with the
REB-specific antibody resulted in 1.8-fold enrichment
-Opioid Receptor and CREB in Nicotine Reward
937Figure 4. Pretreatment with the Opioid Antagonist Naloxone on Test
Day Blocked the Nicotine-Induced Increase in pCREB in the VTA
and NAc and the Corresponding Reinforcing Effects in Wild-Type
Mice
(A) pCREB-positive cells in the VTA on test day of conditioned
place preference. Open bars represent saline pretreatment on test
day, and closed bars represent naloxone pretreatment on test day.
*p < 0.05 from corresponding saline group and corresponding nico-
tine group [F(3, 20) = 97.646; ANOVA with a Bonferroni-Dunn post
hoc; n = 4 per group; mean counts ± SEM].
(B) pCREB-positive cells in the NAc on test day of conditioned
place preference. Open bars represent saline pretreatment on test
day, and closed bars represent naloxone pretreatment on test day.
*p < 0.05 from all groups [F(3, 20) = 5.539; ANOVA with a Bonfer-
roni-Dunn post hoc; n = 4 per group; mean counts ± SEM].
(C) Nicotine-conditioned place preference with naloxone pretreat-
ment on test day only. Open bars represent saline pretreatment,
and dark bars represent pretreatment with naloxone. *p < 0.05 from
corresponding saline-paired group. **p < 0.05 from corresponding
naloxone pretreatment group [F(5, 30) = 17.884; ANOVA with a
Bonferroni-Dunn post hoc; n = 6 per group; mean ± SEM].Figure 5. Naloxone Pretreatment on Test Day Only Does Not Affect
pCREB Induction in the VTA and NAc or Cocaine-Conditioned
Place Preference
(A) pCREB-positive cells in the VTA after test day of conditioned
place preference. Open bars represent saline pretreatment on test
day, and closed bars represent naloxone pretreatment on test day.
There are no significant differences [F(3, 17) = 0.262; ANOVA with a
Bonferroni-Dunn post hoc; n = 4–6 per group; mean counts ± SEM].
(B) pCREB-positive cells in the NAc after test day of conditioned
place preference. Open bars represent saline pretreatment on test
day, and closed bars represent naloxone pretreatment on test day.
*p < 0.05 from corresponding saline-paired groups [F(3, 17) = 5.499;
ANOVA with a Bonferroni-Dunn post hoc; n = 4–6 per group; mean
counts ± SEM].
(C) Cocaine-conditioned place preference with naloxone pretreat-
ment on test day only. Open bars represent saline pretreatment,
and dark bars represent pretreatment with naloxone. *p < 0.05 from
corresponding saline-paired group [F(5, 30) = 6.679; ANOVA with a
Bonferroni-Dunn post hoc; n = 6 per group; mean ± SEM].of MOR promoter DNA from nicotine-treated VTA chro-
matin (Figure 7C), whereas minimal enrichment was ob-
tained when a control IgG was used. In contrast, no
enrichment occurred in saline-treated mice with eitherCREB- or IgG-immunoprecipitated material (Figure 7C).
These data indicate that CREB does not interact in vivo
with the MOR CRE under basal conditions but does so
following nicotine stimulation. These findings are con-
sistent with the mRNA expression data, which demon-
strate similar levels of MOR in wild-type and CREBα
mutant mice, but a lack of upregulation in these mu-
Neuron
938Figure 6. CREBα Mutant Mice Do Not Find Nicotine Rewarding at
1.0 mg/kg Nicotine but Find It Aversive at 2.0 mg/kg Nicotine
Open bars represent wild-type mice, and dark bars represent
CREBα mutant mice. The y axis is expressed as time spent on
nicotine-paired side minus time spent on unpaired side in seconds.
*p < 0.05 from corresponding saline-paired group. **p < 0.05 from
corresponding mutant group [F(5, 30) = 18.127; ANOVA with a Bon-
ferroni-Dunn post hoc; n = 6 per group; mean ± SEM].Figure 7. CREB Binds Directly to -Opioid Receptor Promoter and
Regulates mRNA Levels
(A) CREBα mutant mice do not show an increase in -opioid re-
ceptor (MOR) mRNA in the VTA after nicotine treatment. MOR
mRNA expression in the VTA is increased after nicotine treatment
but not cocaine treatment in wild-type animals only. Mice were
given a saline, nicotine (1 mg/kg), or cocaine (10 mg/kg) injection
once a day every other day for a total of 8 days (four injections).
Twenty-four hours after the last injection, mice were sacrificed, the
VTA was dissected out, and QPCR was performed for the MOR.
The x axis represents the treatment, and the y axis is the ratio of
MOR concentration to the housekeeping gene HPRT concentra-
tion. Open bars represent wild-type animals, and closed bars rep-
resent CREBα mutant animals. *p < 0.05 from wild-type groups
and mutant nicotine group [F(5, 34) = 1.909; ANOVA with a Bonfer-
roni-Dunn post hoc; n = 5–9 per group; mean ± SEM].
(B) MOR mRNA expression in the NAc is not changed after nicotine
injections but is increased in wild-type and CREBα mutant animals
after cocaine treatment. Animals were treated as described above,
only NAc was dissected and PCR was performed on this region.
*p < 0.05 from corresponding saline groups [F(5, 18) = 3.612;
ANOVA with a Bonferroni-Dunn post hoc; n = 4 per group; mean ±
SEM].
(C) (Top) CREB is bound to the CRE element in the promoter of the
MOR 20 min following an acute injection of 1 mg/kg nicotine, but
not saline. Chromatin was immunoprecipitated with an antibody
specific to CREB or a nonrelevant IgG. After purification of the DNA
from the ChIP material, a fragment of the MOR promoter spanning
the CRE was amplified by PCR. PCR products were then visualized
on an ethidium bromide-stained agarose gel. The IgG control
shows no binding, confirming the specificity of the assay. The 28S
ribosomal RNA loci were used as a loading control along with input
genomic DNA as a positive control for the PCR conditions. (Bot-
tom) The CRE site at the MOR promoter was enriched in mice that
received nicotine, but not saline. Fold enrichment was obtained
from QPCR using the loci encoding the 28S rRNAs as the control.
The x axis represents treatment, and the y axis represents the fold
change. Open bars represent saline treatment, and dark bars repre-
sent nicotine treatment. A fold change of 1 indicates no enrich-
ment, whereas fold changes greater than 1 indicate enrichment.tants following nicotine administration. Taken together,
these results demonstrate that CREB is required for
nicotine-mediated MOR upregulation, but not basal
gene transcription.
Nicotine-mediated increases in MOR expression
levels may be related to the behavioral manifestation of
reward. To determine if blockade of the MOR prior to
nicotine administration affects the upregulation of this
receptor, we injected wild-type mice with naloxone
prior to drug treatment using the same injection regi-
men as was used in the place conditioning paradigm
for nicotine or cocaine. Saline-pretreated animals showed
an increase in MOR in the VTA when administered nico-
tine; however, this increase was attenuated in animals
pretreated with naloxone (Figure 8A). In the NAc, pre-
treatment with saline resulted in an increase in MOR
after cocaine administration that was not affected by
pretreatment with naloxone (Figure 8B).
Discussion
Drug-associated cues elicit conditioned neuronal acti-
vation in several brain regions detected by the expres-
sion of the immediate-early gene c-fos (Brown et al.,
1992; Franklin and Druhan, 2000; Schroeder et al.,
2001; Schroeder et al., 2000; Schroeder and Kelley,
2002). Specifically, nicotine-associated sensory cues
have been shown to elicit an increase in Fos expression
in prefrontal cortical and limbic regions (Schroeder et
al., 2001). Clinical studies indicate that exposure to vi-
sual imagery of people smoking in various situations or
cues related to smoking, such as cigarettes or ciga-
rette-related items, can reliably induce smoking urges
in the laboratory (Morgan et al., 1999; Mucha et al.,
1999) and are accompanied by altered glucose metab-
olism in brain regions associated with arousal, sensory
integration, compulsive repetitive behaviors, and mem-
ory (Brody et al., 2002). The present results demon-
strate that nicotine-associated environmental stimuli
-Opioid Receptor and CREB in Nicotine Reward
939Figure 8. Pretreatment with Naloxone Blocks the Nicotine-Induced
Increase in -Opioid Receptor mRNA in the VTA
(A) -opioid receptor mRNA expression in the VTA is increased af-
ter nicotine treatment but not in animals pretreated with naloxone.
Mice were given an injection of naloxone (1 mg/kg s.c.) and 5 min
later were treated with saline, nicotine (1 mg/kg), or cocaine (10
mg/kg) injection once a day every other day for a total of 8 days
(four injections). Twenty-four hours after the last injection, mice
were sacrificed, the VTA was dissected out, and QPCR was per-
formed for the -opioid receptor. The x axis represents the treat-
ment, and the y axis is the ratio of -opioid receptor concentration
to the housekeeping gene HPRT concentration. Open bars repre-
sent wild-type animals, and closed bars represent CREBα mutant
animals. *p < 0.05 from wild-type groups and mutant nicotine group
[F(5, 19) = 3.763; ANOVA with a Bonferroni-Dunn post hoc; n = 5–9
per group; mean ± SEM].
(B) -opioid receptor mRNA expression in the NAc is increased in
wild-type mice after cocaine treatment and is not affected after
pretreatment with naloxone. Animals were treated as described
above, only NAc was dissected and PCR was performed on this
region. *p < 0.05 from corresponding saline groups [F(5, 18) =
3.601; ANOVA with a Bonferroni-Dunn post hoc; n = 4 per group;
mean ± SEM].can activate the same signal transduction molecules as
the drug itself. An increase in pCREB is evident not only
after acute and repeated nicotine administration, but
also following exposure to an environment in which the
animal has previously received nicotine.
The ability of naloxone to block both the conditioned
increase in pCREB as well as behavioral manifestation
of reward suggests that activation of an endogenous
opioid receptor is necessary for these effects. Indeed,
nicotine-stimulated increases in dopamine in the NAc
are dependent upon the activity of MORs located in the
VTA (Tanda and Di Chiara, 1998). Furthermore, previous
results indicate that nicotine is not rewarding in micelacking MORs (Berrendero et al., 2002), and the present
data demonstrate that nicotine-mediated increases in
pCREB are also absent in these mice. The present
series of results extend these finding and demonstrate
that the MOR is required to sustain rewarding proper-
ties of nicotine during reexposure to environmental
cues associated with this drug.
The similarity between effects of a mutation in the
Creb gene and pharmacologic manipulation of the en-
dogenous opioid system on behavioral responses to
nicotine is striking. For example, the effects of nalox-
one administered on test day parallel those of the
CREB deficiency, in that both are capable of blocking
reinforcing, but not aversive properties of nicotine
(compare Figures 4C and 6; nicotine at 2.0 mg/kg). In
addition, a dose of nicotine that elicits reward is ac-
companied by increases of pCREB, which are blocked
by naloxone, while a dose of nicotine that is aversive
does not alter pCREB levels and is not attenuated by
naloxone. Previous studies have suggested that al-
ternate neuroanatomical pathways are responsible for
mediating the reinforcing and aversive properties of ni-
cotine (Laviolette and van der Kooy, 2003a; Laviolette
and van der Kooy, 2003b), and these results confirm a
molecular distinction between reward and aversion.
The results presented above suggest that activation
of both the endogenous opioid system and CREB are
critical for the expression of conditioned nicotine re-
ward; however, the question remains as to how specific
this mechanism is for nicotine. Cocaine shares many of
the downstream effects of nicotine and produces at
least some of its acute reinforcing properties via ac-
tions on the mesolimbic dopamine system (Nestler,
1994). In addition, administration of cocaine has been
shown to induce CREB phosphorylation (Kano et al.,
1995b; Konradi et al., 1994). However, our data indicate
that the mechanism of conditioned drug reward for co-
caine does not rely on the endogenous opioid system.
Cocaine-conditioned place preference was unaffected
by pretreatment with naloxone on test day. Further-
more, pretreatment with naloxone on pairing days does
not prevent the development of conditioned place pref-
erence for cocaine, as was the case for nicotine (data
not shown). In addition, drug-mediated increases in
pCREB, which in this case occur primarily in the NAc
rather than the VTA, are not affected by naloxone.
Lastly, CREB-deficient mice show increases rather than
reductions in cocaine-conditioned place preference
(Walters and Blendy, 2001). Thus, a strong correlation
has been established between a molecular response,
activation of CREB, and a behavioral response, nico-
tine-conditioned reward. While this correlation is spe-
cific for nicotine and not cocaine, further studies with
additional drugs of abuse will be necessary to deter-
mine the extent of this paradigm.
Mechanisms underlying the nicotine-opioid interac-
tion are not well characterized. Previous studies dem-
onstrate that chronic nicotine infusions result in a
downregulation of nicotinic receptor function (Marks et
al., 1993); however, some of the chronic effects of nico-
tine may be attributed to effects on opioid receptor
levels and/or signaling as well. Chronic administration
of nicotine has been shown to upregulate MORs in the
striatum (Wewers et al., 1999). This upregulation could
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tides (Davenport et al., 1990) and subsequent compen- t
satory mechanisms of postsynaptic receptors. 1
A putative downstream target of CREB activation is (
the MOR. DNA sequences in the promoter of the MOR a
gene contain cAMP response elements that are poten- h
tial CREB binding sites (Min et al., 1994). However, the a
presence of the CRE sequence in the promoter or en- p
hancer of a gene alone is not sufficient to characterize m
it as a direct target of CREB, nor does it predict that s
CREB mediates its regulation. There are no differences t
in basal levels of MOR mRNA expression between wild-
type and CREBα mutant mice that could account for E
the difference in nicotine reward in these animals. This
Sis consistent with the role of CREB in activity-depen-
Cdent, and not basal regulation of gene expression and
aconfirmed by our in vivo ChIP data demonstrating that o
CREB is not bound to the MOR promoter in basal con- h
ditions. After nicotine treatment, CREB occupies the f
tMOR promoter, and MOR mRNA expression is in-
1creased in wild-type animals. These data demonstrate
bthat CREB binding in vivo is regulated by nicotine.
gNicotine administration causes a release of endoge-
k
nous opioids in the NAc of rat and striatum of mouse C
(Davenport et al., 1990; Dhatt et al., 1995; Houdi et al., p
1991; Pierzchala et al., 1987; Pomerleau and Pomer-
leau, 1984). Hence, it is possible that this increase in p
endogenous opioids after repeated nicotine treatment F
sis responsible for the subsequent compensatory mech-
5anisms of increased MOR mRNA in the VTA. We hy-
ipothesize that this upregulation is critical for condi-
m
tioned reward behavior. Support for this hypothesis w
comes from the fact that MOR expression is not in- c
creased in CREBα mutant mice following nicotine c
Btreatment, and nicotine reward is absent in these mice.
pFurthermore, pretreatment with naloxone blocks the
Pnicotine-induced increase in MOR in the VTA with no
beffect on the cocaine-induced increase in MOR in the
l
NAc. This lack of upregulation of MOR mRNA could be L
an underlying mechanism for the deficit observed in t
nicotine reward in the CREBα mutant mice as well as L
min mice treated with naloxone; however, additional ex-
mperiments are required to further elucidate the exact
mmechanism by which this occurs.
aThe role of the opioid system in mediating rewarding
c
properties of nicotine is poorly understood. In humans, b
smoking appears to be closely linked to opioid drug F
use (Mello et al., 1980), and endogenous opioid levels i
care increased following smoking, paralleling increases
uin plasma nicotine levels (Pomerleau et al., 1983). How-
bever, clinical studies examining the efficacy of opioid
dreceptor antagonists to block cigarette craving so far a
have produced mixed results ranging from ineffec- t
tiveness at smoking cessation to mild reductions in the d
desire to smoke (Covey et al., 1999; King and Meyer,
f2000; Wong et al., 1999). In our studies, we trained ani-
wmals to develop a preference for nicotine and were able
pto block that preference with naloxone when animals
s
were reexposed to the environment associated with
nicotine, but in the absence of the drug itself. These
P
data suggest that the timing and context of opioid re- P
ceptor antagonist administration are critical for deter- c
mining the effectiveness of blocking nicotine reward. t
cStudies reporting a negative effect of opioid antago-ists on smoking behavior in humans have adminis-
ered opioid antagonists either chronically (Wong et al.,
999) or 1 (Nemeth-Coslett and Griffiths, 1986) to 24 hr
Sutherland et al., 1995) prior to smoking a cigarette,
nd subsequent smoking behavior was evaluated in a
ospital or laboratory setting, clearly not environments
ssociated with cigarette smoking. Given the results re-
orted here, clinical studies designed to evaluate ad-
inistration of opioid antagonists just prior to cues as-
ociated with smoking could lead to a more promising
reatment regimen.
xperimental Procedures
ubjects
REBaD mice were generated as previously described (Blendy et
l., 1996; Hummler et al., 1994) and are maintained as F1 hybrids
f 129SvEvTac:C57/BL/6. The parental strains for this hybrid line
ave been backcrossed with vendor-supplied wild-type strains
or several generations. For all experiments, mutants and wild-
ype controls are obtained from crossing heterozygote CREBaD
29SvEvTac N10 with heterozygote CREBaD C57BL/6 N12. This
reeding scheme allows us to rigorously control for a uniform
enetic background of experimental animals over time. MOR
nockout mice and wild-type control mice were maintained in a
57BL/6 background. MOR knockout mice were generously sup-
lied by Dr. John Pintar (Rutgers University).
CREB Immunohistochemistry
or acute studies, wild-type mice were given an injection of either
aline or naloxone (1.0 mg/kg s.c.; Sigma, St. Louis, MO) followed
min later by a single injection of saline or nicotine (1.0 mg/kg
.p.; nicotine hydrogen tartrate salt; Sigma, St. Louis, MO). Twenty
inutes after this injection, mice were anesthetized and perfused
ith 4% paraformaldehyde. Brains were removed and sectioned
oronally on a cryostat at 40 M. Processing for pCREB-positive
ells was performed as previously described (Walters et al., 2003).
riefly, sections were blocked in BSA and incubated in primary
hospho-CREB antibody (1:1000; Upstate Biotechnologies, Lake
lacid, NY) for two nights at 4°C. Sections were then incubated in
iotinylated secondary antibody (1:200; Vector Laboratories, Bur-
ingame, CA) followed by Avidin-Biotin Complex (1:500; Vector
aboratories, Burlingame, CA). Bound antibody was visualized
hrough incubation in 0.02% 3,3#-diaminobenzidine (Sigma, St.
ouis, MO) with 0.02% hydrogen peroxide for 5 min. Slices were
ounted, dehydrated, and cover-slipped with Permount mounting
edium. Brain regions counted were identified by their approxi-
ate stereotaxic coordinates (Franklin and Paxinos, 1997), which
re as follows: VTA, bregma −3.64; NAc, bregma 1.10; cingulated
ortex, bregma 1.10; substantia nigra, bregma −3.64; striatum,
regma 1.10; PPT, bregma −4.36; and hippocampus, bregma −1.70.
or specific atlas identification of regions counted, see Figure S1
n the Supplemental Data available with this article online. Quantifi-
ation of pCREB-immunolabeled nuclear profiles was performed
sing Image-Pro Plus (Media Cybernetics Inc., Silver Spring, MD)
y an individual blind to the treatments. The appropriate area was
igitally imaged, and pCREB staining was subject to a threshold
nd counted. Profiles were counted in representative serial sec-
ions with comparable sections chosen for comparison between
rug and saline groups.
For place conditioning studies, place conditioning was per-
ormed as described below. Immediately following the test, mice
ere removed from the cages, anesthetized, and perfused with 4%
araformaldehyde. Brains were then processed for pCREB as de-
cribed previously (Walters et al., 2003).
lace Conditioning
lace conditioning boxes consist of two distinct sides (20 cm × 20
m × 20 cm). A partition separates the two sides with an opening
hat allows access to either side of the chamber, and this partition
an be closed off for pairing days.
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On day 1, animals were placed in the boxes and allowed to roam
freely from side to side for 15 min, and time spent in each side was
recorded. These data were used to separate the animals into
groups of approximately equal bias.
Conditioning Phase
Animals were paired for 30 min with the saline group receiving sa-
line in both sides of the boxes and drug groups receiving nicotine
at 1.0 mg/kg or 2.0 mg/kg (nicotine hydrogen tartrate salt; Sigma,
St. Louis, MO) or cocaine at 10.0 mg/kg (NIDA Drug Supply, Re-
search Triangle Park, NC) on one of the sides and saline on the
opposite side. Drug-paired sides were randomized among all
groups. Conditioning lasted for 8 days, with animals in the drug
group receiving drug every other day.
Test Phase
On the test day, animals were all given a saline injection and al-
lowed to roam freely between the two sides. Time spent on each
side was recorded, and data are expressed as time spent on drug-
paired side minus time spent on saline-paired side. A positive num-
ber indicates a preference for the drug-paired side, while a nega-
tive number indicates an aversion to the drug-paired side. A
number at or near zero indicates no preference for either side.
For studies with naloxone pretreatment, place conditioning was
performed as described previously. Animals received saline or nal-
oxone (1.0 mg/kg s.c.) 5 min prior to saline injection on the test
day only.
Real-Time Quantitative PCR
Animals were sacrificed during the light phase of the light/dark cy-
cle. Following cervical dislocation, brains were dissected for RNA
preparation. RNA was isolated using guanidine isothiocyanate
(Chomczynski and Sacchi, 1987). The quality of the RNA samples
was determined by ethidium bromide staining of 18S and 28S
rRNAs following fractionation on denaturing agarose gels. High-
quality total RNA samples from the VTA and NAc of individual
animals were reverse transcribed using 1 g Oligo (dT) primer, Su-
perscript II Reverse Transcriptase, and accompanying reagents (In-
vitrogen) at 42°C for 1 hr. VTA and NAc cDNA was used at a 1:3
dilution in water in subsequent real-time PCR reactions.
PCR reaction mixes were assembled using the Brilliant SYBR
Green QPCR Master Mix (Stratagene), 10 M primers, and the in-
cluded reference dye at a 1:200 dilution according to the manufac-
turer’s instructions, except that the total reaction volume was
scaled down from 50 l to 25 l. Reactions were performed us-
ing the SYBR Green (with Dissociation Curve) program on the
Prism7000 Multiplex Quantitative PCR System (ABI). Cycling
parameters were 95°C for 10 min and then 40 cycles of 95°C (30 s),
58°C or 60°C (1 min), and 72°C (30 s) followed by a melting curve
analysis. All reactions were performed in triplicate with reference
dye normalization, and the median cycle threshold value was used
for analysis. Primer sequences are available upon request.
ChIP
Twenty minutes following an acute injection of saline or nicotine
(1.0 mg/kg i.p.; nicotine hydrogen tartrate salt; Sigma, St. Louis,
MO), wild-type mice were killed, the brains were removed, and the
VTA was dissected out and immediately flash frozen in liquid ni-
trogen.
Following dissection, four macrodissected VTAs were pooled,
minced in cold PBS, and then crosslinked using 1% formaldehyde/
PBS for 10 min. The crosslinking was quenched by the addition of
glycine to a final concentration of 0.125 M. The samples were
washed once with cold PBS and Dounce homogenized in ChIP ly-
sis buffer (10 mM NaCl/3 mM MgCl2/0.5% NP-40/10 mM Tris-HCl
[pH 8.1] plus protease inhibitors). After 5 min on ice, nuclei were
sedimented by centrifugation. The pellet was then resuspended in
nuclear lysis buffer (1% SDS/5 mM EDTA [pH 8.0]/50 mM Tris-HCl
[pH 8.1]/protease inhibitors). Following a 5 min incubation on ice,
the lysate was sonicated (Sonic Dismembrator Model 100-Fisher)
using three pulses for 20 s at 4–6 W. Insoluble debris was removed
by centrifugation, and the supernatant was collected and flash fro-
zen in liquid nitrogen. An input fraction was generated by uncross-
linking nonimmunoprecipitated chromatin material. Appropriate frag-mentation of the chromatin was assessed by agarose gel elec-
trophoresis, with a goal of DNA fragments of approximately 300–
700 bp in length. Chromatin DNA concentrations were calculated
by measuring A260 on a Nanodrop ND-1000 (Nanodrop).
Two micrograms of chromatin was used for each immunoprecipi-
tation. The chromatin was precleared by incubating with protein-G
agarose at 4°C for 1 hr. Ten micrograms of antiserum raised against
CREB (Upstate) or 2 g of preimmune IgG (Santa Cruz) was added,
and the samples were rotated at 4°C overnight. Immunoprecipi-
tates were isolated by incubating with blocked protein-G agarose
and washed at room temperature with the following buffers: low-
salt wash buffer (0.1% SDS/1% Triton X-100/2 mM EDTA/20 mM
Tris-HCl [pH 8.1]/150 mM NaCl), high-salt wash buffer (0.1% SDS/
1% Triton X-100/2 mM EDTA/20 mM Tris-HCl [pH 8.1]/500 mM
NaCl), LiCl wash buffer (0.25 M LiCl/1% Nonidet P-40/1% de-
oxycholate/1 mM EDTA/10 mM Tris-HCl [pH 8.1]) and 1× TE buffer.
Chromatin was eluted from the antibody by incubation for 10 min
at room temperature with elution buffer (0.1 M NaHCO3/1% SDS).
Chromatin was uncrosslinked by adding NaCl to 0.2 M and incubat-
ing at 65°C for at least 4 hr. Samples were then digested with 40
ng of proteinase K and DNA isolated by Quiquick columns (Qiagen).
Promoter enrichment was visualized on ethidium bromide-stained
agarose gels and quantified by real-time quantitative PCR. Pro-
moter enrichment was calculated by comparing the difference in
abundance of the control DNA sequences (28S rRNA loci) to the
promoter sequence of interest (MOR) in genomic DNA (input) to the
immunoprecipitated DNA. The loci encoding the 28S ribosomal
RNA were used as our normalization sequence, as these se-
quences are not bound by CREB. Primer sequences are available
upon request.
Supplemental Data
One supplemental figure can be found with this article online at
http://www.neuron.org/cgi/content/full/46/6/933/DC1/.
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